Indo Us Bio-Tech
86.65
+0.83(+0.97%)
Market Cap₹173.75 Cr
PE Ratio78.58
IndustryFMCG
Company Performance:
1D+0.97%
1M-6.51%
6M-22.04%
1Y-56.23%
5Y-70.39%
View Company Insightsright
More news about Indo Us Bio-Tech
22May 26
Indo Us Bio Tech board to meet on May 29 to consider Q4FY26 results
Indo Us Bio Tech Limited will hold a board meeting on May 29, 2026, to approve the audited financial results for the quarter and year ending March 31, 2026. The trading window is closed from April 1 to May 30, 2026.
 no imag found
23Apr 26
Indo US Bio-Tech Appoints Mrs. Hemanshi Darsh Soni as Independent Director
Indo US Bio-Tech Limited has appointed Mrs. Hemanshi Darsh Soni (DIN: 11659183) as Additional Director in Non-Executive Independent Director capacity for 5 years from 21.04.2026, subject to shareholder approval. She brings service sector experience in building high-performance teams and operational processes, with no relationships to existing directors and no other listed entity directorships. The appointment complies with SEBI regulations and strengthens board independence.
 no imag found
23Apr 26
Indo US Bio-Tech Limited Announces Resignation of Independent Director Mrs. Nehaben Sachinbhai Patel
Indo US Bio-Tech Limited announced the resignation of Mrs. Nehaben Sachinbhai Patel (DIN: 09263180) as Non-Executive Independent Director effective April 21, 2026. The resignation was submitted due to personal and unavoidable reasons, with proper regulatory disclosures made to BSE and NSE on April 22, 2026. Mrs. Patel confirmed no other material reasons for departure and does not hold directorship in any other listed entity.
 no imag found
06Apr 26
Indo Us Bio-Tech Limited Submits SEBI Compliance Certificate for FY2026
Indo Us Bio-Tech Limited filed its SEBI compliance certificate under Regulation 74(5) for the year ended March 31, 2026. The certificate, issued by registrar Bigshare Services Private Limited, confirms no securities were received for dematerialization during the quarter. The company submitted this mandatory compliance document to BSE and NSE on April 6, 2026, maintaining its regulatory obligations.
 no imag found
11Mar 26
Indo Us Bio-Tech Limited Issues Clarification on Recent Stock Price Movement
Indo Us Bio-Tech Limited issued a clarification on March 11, 2026, regarding significant stock price movement observed on March 10, 2026. The company stated it has no undisclosed material information that could affect share price and attributed the movement to market-driven investor sentiment. The management confirmed compliance with SEBI disclosure requirements and emphasized that all price-sensitive information has been promptly disclosed.
 no imag found
05Mar 26
Indo-US Agriseeds Limited Reduces Stake in Indo US Bio-Tech Limited Through Open Market Sale
Indo-US Agriseeds Limited disclosed the sale of 50,000 shares in Indo US Bio-Tech Limited through open market transactions on March 2, 2026, reducing its shareholding from 9.0742% to 8.8249%. The transaction was reported under SEBI Takeover Regulations, with the company maintaining its promoter group status in the target company. Indo US Bio-Tech Limited has an equity share capital of 2,00,52,000 shares and is listed on BSE and NSE.
 no imag found
12Feb 26
Indo-US Agriseeds continues stake reduction with 75,000 share sale
Indo-US Agriseeds Limited has disclosed another share sale in Indo US Bio-Tech Limited, selling 75,000 equity shares through open market operations on February 11, 2026. This latest transaction reduced the company's shareholding from 19,44,569 shares (9.6976%) to 18,69,569 shares (9.3236%) of the total voting capital.
 no imag found
21Jan 26
Indo US Bio-Tech Reports Q3 FY26 Results with Net Profit of ₹299.66 Lakhs
Indo US Bio-Tech Limited reported Q3 FY26 net profit of ₹299.66 lakhs, down 40.7% from ₹505.45 lakhs in Q3 FY25, while revenue declined marginally to ₹2,279.83 lakhs. Nine-month performance showed revenue growth of 19.8% to ₹8,441.44 lakhs, though net profit decreased 11.4% to ₹1,115.11 lakhs. The auditors expressed qualified opinion due to incomplete assessment of new Labour Codes impact.
 no imag found
29Dec 25
Indo US Bio-Tech Receives ED Summons Under PMLA for Inquiry Purposes
Indo US Bio-Tech Limited has received summons from the Directorate of Enforcement (ED) under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the company's Principal Officer to appear and produce specific information and documents for investigation. The company stated that no formal charges have been made and no immediate material impact on financial or operational activities is expected. The disclosure was made to stock exchanges on December 29, 2025, with the company acknowledging a delay in reporting due to internal review processes.
 no imag found
Indo Us Bio-Tech
86.65
+0.83
(+0.97%)
1 Year Returns:-56.23%
Industry Peers
LT Foods
378.65
(-0.36%)
KRBL
350.30
(-1.34%)
Kaveri Seed Company
855.40
(-1.39%)
Trualt Bioenergy
430.60
(+2.66%)
Sanstar
106.48
(-1.20%)
GRM Overseas
90.14
(-1.35%)
Gulshan Polyols
186.93
(+3.37%)